# China NMPA Drug Inspection - Anhui Bozhou Jinshaotang Traditional Chinese Medicine Pieces Co., Ltd. - Moneywort

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-bozhou-jinshaotang-traditional-chinese-medicine-pieces-co-ltd/ffd8d911-9f53-4a86-8528-db42db3f189d/
Source feed: China

> China NMPA drug inspection for Anhui Bozhou Jinshaotang Traditional Chinese Medicine Pieces Co., Ltd. published January 18, 2018. Drug: Moneywort. The Ningxia Food and Drug Administration issued an announcement on January 18, 2018, detailing the outcomes of a regiona

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Ningxia Drug Quality Sampling Inspection Information Bulletin (No. 01, 2018)
- Company Name: Anhui Bozhou Jinshaotang Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-01-18
- Drug Name: Moneywort
- Inspection Finding: Properties
- Action Taken: The relevant municipal and county market supervision administrations have conducted an investigation and handled the matter in accordance with the law.
- Summary: The Ningxia Food and Drug Administration issued an announcement on January 18, 2018, detailing the outcomes of a regional drug quality sampling inspection conducted throughout 2017. The inspection covered 58 batches from 38 drug varieties, primarily traditional Chinese medicine decoction pieces, but also including some chemical drugs. Nine varieties across 17 batches were found to be non-compliant with established quality standards. 

Multiple companies were implicated, including Ningxia Yongshoutang Traditional Chinese Medicine Processed Slices Co., Ltd., Ningxia Baicaowang Pharmaceutical Co., Ltd., Ningxia Mingde Traditional Chinese Medicine Slices Co., Ltd., Anhui Huilong Traditional Chinese Medicine Slices Co., Ltd., and Hangzhou Huadong Pharmaceutical Group Xinwufeng Pharmaceutical Co., Ltd. The main violations identified encompassed issues such as incorrect appearance, failures in physicochemical tests, discrepancies in thin-layer chromatography, improper ash content, and inaccurate content determination. These products were assessed against the regulatory framework of the Chinese Pharmacopoeia (primarily the 2015 Edition, Parts I and II) and, in one instance, the Ministry of Health Drug Standards. 

For the non-compliant drugs, the relevant municipal and county market supervision administrations were tasked with conducting investigations and taking appropriate legal action.

Company: https://www.globalkeysolutions.net/companies/anhui-bozhou-jinshaotang-traditional-chinese-medicine-pieces-co-ltd/7f060a83-9bde-4eec-91de-ef9b7e2f83b0/